MindWalk Holdings Corp. (HYFT), a biotechnology firm specializing in AI-driven drug discovery, faces significant Shariah compliance challenges primarily due to a high interest income ratio of 89.28%, which exceeds the 5% threshold across all major standards. While its core business activities in biologics development are permissible, the financial screening criteria result in non-compliance under AAOIFI, MSCI, and S&P methodologies. The company is excluded from all major Shariah indices, leading to an overall non-compliant status. ESG factors are positive with low risk, and no controversies impact compliance. Investors may consider purification of 89.28% for any dividends, but alternatives in the sector are recommended.